Considering temozolomide as a novel potential treatment for esophageal cancer

Cancer

Volumn 117, Issue 9, 2011, Pages 2004-2016

  Bruyère, Céline ^e   Lonez, Caroline ^a   Duray, Anaelle ^b   Cludts, Stéphanie ^b   Ruysschaert, Jean Marie ^a   Saussez, Sven ^b   Yeaton, Paul ^c   Kiss, Robert ^a,d   Mijatovic, Tatjana ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b UNIVERSITY OF MONS   (Belgium)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e NONE

Author keywords

C X C chemokine; chemokine receptor; esophageal cancer; temozolomide

Indexed keywords

CISPLATIN; CXCL2 CHEMOKINE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CHEMOKINE CXCL12; DACARBAZINE; ESOPHAGEAL NEOPLASMS; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955423865     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25687     Document Type: Article

References (38)

1. Homs MY, Voest EE, Siersema PD., Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs. 2009; 14: 329-339.
2. Li B, Li YY, Tsao SW, et al. Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther. 2009; 8: 2635-2644.
3. Malthaner RA, Collin S, Fenlon D., Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev. 2006; (3): CD001556.
4. Casson AG, Tammemagi M, Eskandarian S, et al. p53 Alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival. Mol Pathol. 1998; 51: 71-79. (Pubitemid 28261244)
5. Li J, Minnich DJ, Camp ER, Brank A, Mackay SL, Hochwald SN., Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-kappaB. J Surg Res. 2006; 132: 112-120.
6. D'Amico TA, Harpole DH Jr,. Molecular biology of esophageal cancer. Chest Surg Clin North Am. 2000; 10: 451-469. (Pubitemid 30627541)
7. Lefranc F, Facchini V, Kiss R., Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist. 2007; 12: 1395-1403.
8. Lefranc F, Brotchi J, Kiss R., Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005; 23: 2411-2422. (Pubitemid 46218735)
9. Le Calve B, Ryntowski M, Le Mercier M, et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia. 2010; 12: 727-739.
10. Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006; 42: 768-778.
11. Balkwill F., Cancer and the chemokine network. Nat Rev Cancer. 2004; 4: 540-550. (Pubitemid 38868623)
12. Fernandez EJ, Lolis E., Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002; 42: 469-499. (Pubitemid 34160533)
13. Waugh DJ, Wilson C., The interleukin-8 pathway in cancer. Clin Cancer Res. 2008; 14: 6735-6741.
14. Jenkins GJ, Mikhail J, Alhamdani A, et al. Immunohistochemical study of nuclear factor-kappaB activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. J Clin Pathol. 2007; 60: 1232-1237. (Pubitemid 350084544)
15. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, et al. Elevation of circulating interleukin-8 is related to lymph node and distant metastases in esophageal squamous cell carcinomas-implication for clinical evaluation of cancer patient. Cytokine. 2008; 41: 232-239.
16. Ren Y, Law S, Huang X, et al. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 2005; 242: 55-63. (Pubitemid 40917968)
17. Ren Y, Cao B, Law S, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 2005; 11: 6190-6197. (Pubitemid 41262947)
18. Gockel I, Schimanski CC, Heinrich C, et al. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma [serial online]. BMC Cancer. 2006; 6: 290.
19. Sasaki K, Natsugoe S, Ishigami S, et al. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncol Rep. 2009; 21: 65-71.
20. Sasaki K, Natsugoe S, Ishigami S, et al. Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. J Surg Oncol. 2008; 97: 433-438. (Pubitemid 351466387)
21. Kaifi JT, Yekebas EF, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005; 97: 1840-1847. (Pubitemid 43033904)
22. Wang B, Hendricks DT, Wamunyokoli F, et al. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res. 2006; 66: 3071-3077.
23. Van Quaquebeke E, Simon G, Andre A, et al. Identification of a novel cardenolide (2ââ-oxovorusharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance: structure-activity relationship analyses. J Med Chem. 2005; 48: 849-856. (Pubitemid 40209107)
24. Lefranc F, Mijatovic T, Kondo Y, et al. Targeting the alpha-1 subunit of the sodium pump (the Na+/K+-ATPase) to combat glioblastoma cells. Neurosurgery. 2008; 62: 211-222.
25. Mathieu V, Le Mercier M, De Neve N, et al. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol. 2007; 127: 2399-2410. (Pubitemid 47619747)
26. Elouahabi A, Flamand V, Ozkan S, et al. Free cationic liposomes inhibit the inflammatory response to cationic lipid-DNA complex injected intravenously and enhance its transfection efficiency. Mol Ther. 2003; 7: 81-88. (Pubitemid 36305361)
27. De Hauwer C, Camby I, Darro F, et al. Gastrin inhibits motility, decreases cell death and increases cell proliferation in human glioblastoma cell lines. J Neurobiol. 1998; 37: 373-382. (Pubitemid 28506921)
28. Debeir O, Megalizzi V, Warzee N, et al. Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res. 2008; 314: 2985-2998.
29. Gordower L, Decaestecker C, Kacem Y, et al. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol Appl Neurobiol. 1999; 25: 319-330. (Pubitemid 29392712)
30. Mathieu V, Mijatovic T, Van Damme M, et al. Gastrin exerts pleiotropic effects on human melanoma cell biology. Neoplasia. 2005; 7: 930-943.
31. Wang B, Khachigian LM, Esau L, et al. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Mol Cancer Res. 2009; 7: 755-764.
32. Mathieu V, De Neve N, Le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008; 10: 1383-1392.
33. Benezra R, Rafii S, Lyden D., The Id proteins and angiogenesis. Oncogene. 2001; 20: 8334-8341. (Pubitemid 34121904)
34. Kanzawa T, Germano IM, Komata T, et al. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004; 11: 448-457. (Pubitemid 38489422)
35. Katayama M, Kawaguchi T, Berger MS, et al. DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ. 2007; 14: 548-558.
36. Roos WP, Batista LF, Naumann SC, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2007; 26: 186-197. (Pubitemid 46095730)
37. Lasorella A, Rothschild G, Yokota Y, et al. ID2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol. 2005; 25: 3563-3574. (Pubitemid 40559563)
38. Noma K, Smalley KS, Lioni M, et al. The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterology. 2008; 134: 1981-1993. (Pubitemid 351790740)